Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Current Assets for 9 consecutive years, with $900.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 4.19% to $900.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $900.7 million through Dec 2025, up 4.19% year-over-year, with the annual reading at $900.7 million for FY2025, 4.19% up from the prior year.
  • Current Assets for Q4 2025 was $900.7 million at Denali Therapeutics, up from $882.6 million in the prior quarter.
  • The five-year high for Current Assets was $1.4 billion in Q1 2021, with the low at $864.4 million in Q4 2024.
  • Average Current Assets over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2021.
  • Peak annual rise in Current Assets hit 139.85% in 2021, while the deepest fall reached 40.01% in 2021.
  • Over 5 years, Current Assets stood at $897.2 million in 2021, then surged by 52.95% to $1.4 billion in 2022, then decreased by 22.46% to $1.1 billion in 2023, then fell by 18.77% to $864.4 million in 2024, then increased by 4.19% to $900.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $900.7 million, $882.6 million, and $934.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.